TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have earned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $102.00.

TMDX has been the subject of a number of research analyst reports. Oppenheimer lifted their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. Piper Sandler initiated coverage on TransMedics Group in a report on Thursday, March 28th. They set an “overweight” rating and a $95.00 price target on the stock. JPMorgan Chase & Co. raised their price target on TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Finally, Morgan Stanley increased their target price on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th.

Insider Transactions at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 15,512 shares of the business’s stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total transaction of $1,403,060.40. Following the completion of the sale, the insider now owns 25,185 shares of the company’s stock, valued at $2,277,983.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Tamer I. Khayal sold 15,512 shares of TransMedics Group stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total transaction of $1,403,060.40. Following the transaction, the insider now directly owns 25,185 shares of the company’s stock, valued at approximately $2,277,983.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Tamer I. Khayal sold 2,330 shares of the business’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $90.09, for a total value of $209,909.70. Following the transaction, the insider now owns 14,375 shares of the company’s stock, valued at $1,295,043.75. The disclosure for this sale can be found here. Insiders sold 115,408 shares of company stock worth $9,802,401 in the last three months. Corporate insiders own 6.70% of the company’s stock.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently modified their holdings of TMDX. Ancora Advisors LLC purchased a new stake in TransMedics Group in the 1st quarter worth $38,000. First Horizon Advisors Inc. raised its stake in TransMedics Group by 45.1% during the 1st quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock valued at $41,000 after purchasing an additional 169 shares during the period. Belpointe Asset Management LLC boosted its stake in TransMedics Group by 51.6% in the 1st quarter. Belpointe Asset Management LLC now owns 558 shares of the company’s stock worth $42,000 after purchasing an additional 190 shares during the period. PNC Financial Services Group Inc. boosted its stake in TransMedics Group by 595.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 598 shares of the company’s stock worth $50,000 after purchasing an additional 512 shares during the period. Finally, Point72 Hong Kong Ltd purchased a new position in shares of TransMedics Group in the fourth quarter worth $47,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Down 5.8 %

Shares of TransMedics Group stock opened at $87.86 on Thursday. The company has a 50-day simple moving average of $83.01 and a two-hundred day simple moving average of $72.88. TransMedics Group has a 52-week low of $36.42 and a 52-week high of $99.63. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The stock has a market capitalization of $2.87 billion, a PE ratio of -114.10 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The business had revenue of $81.20 million for the quarter, compared to the consensus estimate of $68.49 million. During the same period last year, the business posted ($0.21) EPS. The company’s revenue was up 158.6% compared to the same quarter last year. On average, analysts anticipate that TransMedics Group will post -0.14 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.